Oncology Learning Network

@OncLearnNetwork

Oncology Learning Network® is an online resource for the latest news and updates in oncology practice.

East Windsor, NJ
Vrijeme pridruživanja: travanj 2018.

Tweetovi

Blokirali ste korisnika/cu @OncLearnNetwork

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @OncLearnNetwork

  1. Prikvačeni tweet
    Poništi
  2. For , we're offering $50 off the price of registration to select OLN live conferences: , , and . Register by Wednesday Feb. 5 using code WORLDCANCER at checkout:

    Poništi
  3. Dr Iyengar, , discusses the pros and cons of using proton therapy in the management of patients with stage III in this short video from the 2019 meeting. Watch:

    Poništi
  4. Findings from a meta-analysis of patients with bone metastases from treated with bone-targeted radioisotopes (RIs) suggest there may be survival benefits with α- versus β-emitting RIs. More:

    Poništi
  5. Today is the final day to take advantage of early registration discounts for LA! Save $50 by registering tonight before midnight EST:

    Poništi
  6. proslijedio/la je Tweet

    Today is the final day to take advantage of early registration discounts for LA! Save $50 by registering tonight before midnight EST:

    Poništi
  7. Recurrence scores may help predict locoregional recurrence that could aid in treatment decision-making for postmenopausal patients with breast cancer. Full story:

    Poništi
  8. proslijedio/la je Tweet
    29. sij

    Among patients in a multi-center study with colorectal cancer (CRC) with ypStage II and III disease after presurgery chemoradiotherapy (CRT), adjuvant oxaliplatin, leucovorin, and fluorouracil bolus (FOLFOX) improved disease-free survival:

    Poništi
  9. In this podcast, , , discusses results from a phase 1 trial which evaluated asciminib, an ABL1 kinase inhibitor, in patients with heavily pretreated . Listen here:

    Poništi
  10. proslijedio/la je Tweet

    Early rates for NYC are in effect for just 4 more weeks. Don't forget: We have new, lower prices in 2020 for nurses, students, residents & fellows:

    Poništi
  11. To better understand the characteristics of relapse in , Benshang Li, MD, et al carried out whole-genome and ultra-deep sequencing of serial samples from 16 patients. Full recap of findings:

    Poništi
  12. True or False? There is no benefit to continuing a full induction regimen until progression without a period of observation or maintenance therapy in patients with metastatic cancer. Take the quiz:

    Poništi
  13. Loretta Nastoupil, MD, , discusses results from a study exploring obinutuzumab therapy plus lenalidomide in patients with untreated, high tumor burden FL. Watch here:

    Poništi
  14. Researchers suggest that patients with muscle-invasive who are more likely to receive neoadjuvant versus adjuvant chemotherapy have increased overall survival. Read more:

    Poništi
  15. proslijedio/la je Tweet

    If you enjoy the Lymphoma, Leukemia & Myeloma Congress: The same team behind this event also puts on - a debate-style meeting with 3 locations in 2020:

    Poništi
  16. The has approved tazemetostat for the treatment of patients with metastatic or locally advanced epithelioid sarcoma ineligible for complete resection. Read more:

    Poništi
  17. In this panel discussion, , , and Dr. Stephen Ansell share key updates on the use of brentuximab vedotin for the treatment of classical Hodgkin . Check out the 6-part series here:

    Poništi
  18. “Concurrent chemoradiotherapy administered with proton therapy might reduce toxicity and achieve comparable cancer control outcomes compared with conventional photon radiotherapy..." Read more study findings from investigators here:

    Poništi
  19. Rimas Orentas, PhD, discusses CAR-T resistance in patients with B-ALL and results from an analysis presented at the 2019 ASH Annual Meeting. Read this short interview here:

    Poništi
  20. Poništi
  21. Results from a study comparing outcomes of patients with lymphoma or treated with idelalisib in clinical trials vs the clinical setting showed less favorable outcomes in the clinical setting. Read more here:

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·